Literature DB >> 23313007

Temporal trends in medication use and outcomes in atrial fibrillation.

Louise Pilote1, Mark J Eisenberg, Vidal Essebag, Jack V Tu, Karin H Humphries, Sylvie S L Leung Yinko, Hassan Behlouli, Helen Guo, Cynthia A Jackevicius.   

Abstract

BACKGROUND: Novel therapies for anticoagulation and rhythm control for atrial fibrillation (AF) have been developed recently. To best evaluate the comparative effectiveness of newer agents, practice patterns and outcomes of existing therapies must be characterized at the population level.
METHODS: We conducted a retrospective population-based cohort study of patients ≥ 65 years with a first diagnosis of AF over a 9-year period in Québec and Ontario. Using hospital and drug claims databases, trends of filled prescriptions, and rates of strokes, bleeding complications, and mortality within 1 year were estimated.
RESULTS: From 1998 to 2006, 338, 479 patients were hospitalized with an AF diagnosis. Median age was 77.5 years and 50.4% were male. Use of rate control was 3-fold higher than rhythm control therapy. There was a modest decrease in rate control therapy until 2001 (71.9% to 70.6%, P = 0.01), followed by a progressive increase (70.6% to 76.4%, P = 0.014). An opposite trend was observed for rhythm control. Although warfarin prescriptions increased (51.0% to 64.5%, P < 0.0001), stroke rates tended to decrease (3.8% to 3.5%, P = 0.148). Bleeding complications increased mostly because of emergency room visits (4.8% to 6.1%, P = 0.007). Mortality remained high despite a small but statistically significant decline (27.6% to 25.8%, P = 0.018).
CONCLUSIONS: With increased anticoagulation use, stroke rates are declining and emergency room bleeding complications are increasing. Despite an increased use of evidence-based AF therapies, mortality remains high in this population. These findings highlight the need to focus on AF prevention in addition to minimizing its complications.
Copyright © 2013 Canadian Cardiovascular Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313007     DOI: 10.1016/j.cjca.2012.09.021

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  12 in total

1.  Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.

Authors:  Kourosh Ravvaz; John A Weissert; Christian T Ruff; Chih-Lin Chi; Peter J Tonellato
Journal:  Circ Cardiovasc Genet       Date:  2017-12

2.  Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study.

Authors:  Endalkachew Admassie; Leanne Chalmers; Luke R Bereznicki
Journal:  Eur J Clin Pharmacol       Date:  2017-09-22       Impact factor: 2.953

3.  Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Authors:  Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara
Journal:  Intern Emerg Med       Date:  2021-12-02       Impact factor: 5.472

4.  Current Evidence and Recommendations for Rate Control in Atrial Fibrillation.

Authors:  Abhishek Maan; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

5.  Evaluating the potential for pharmacists to prescribe oral anticoagulants for atrial fibrillation.

Authors:  Roopinder K Sandhu; Lisa M Guirguis; Tammy J Bungard; Erik Youngson; Lisa Dolovich; Jamie C Brehaut; Jeff S Healey; Finlay A McAlister
Journal:  Can Pharm J (Ott)       Date:  2017-11-29

6.  Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation.

Authors:  Moti Haim; Moshe Hoshen; Orna Reges; Yardena Rabi; Ran Balicer; Morton Leibowitz
Journal:  J Am Heart Assoc       Date:  2015-01-21       Impact factor: 5.501

7.  Impact of Rural Residence on Warfarin Use and Clinical Events in Patients with Non-Valvular Atrial Fibrillation: A Canadian Population Based Study.

Authors:  Cynthia Wu; Michael Sean McMurtry; Roopinder K Sandhu; Erik Youngson; Justin A Ezekowitz; Padma Kaul; Finlay A McAlister
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

8.  Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study.

Authors:  Amy Y X Yu; Shaun Malo; Lawrence W Svenson; Stephen B Wilton; Michael D Hill
Journal:  J Am Heart Assoc       Date:  2017-10-28       Impact factor: 5.501

Review 9.  Mortality in atrial fibrillation. Is it changing?

Authors:  Alvaro Alonso; Zakaria Almuwaqqat; Alanna Chamberlain
Journal:  Trends Cardiovasc Med       Date:  2020-10-27       Impact factor: 6.677

10.  Cardiac glycosides use and the risk of lung cancer: a nested case-control study.

Authors:  Sébastien Couraud; Laurent Azoulay; Sophie Dell'Aniello; Samy Suissa
Journal:  BMC Cancer       Date:  2014-08-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.